Advertisement

EU drugs regulator approves new single dose vaccine

Author thumbnail
AFP/The Local - [email protected]
EU drugs regulator approves new single dose vaccine
(FILES) This file photo taken on November 17, 2020 in London shows vials with Covid-19 Vaccine stickers attached and syringes with the logo of US pharmaceutical company Johnson & Johnson. - The European Medicines Agency said on March 9, 2021 that it is set to decide whether to authorise Johnson & Johnson's Janssen single-shot coronavirus vaccine for the EU on March 11. If approved by the Amsterdam-based regulator, the vaccine would be the fourth to get the green light for the 27-nation bloc, in a boost for its slow-starting vaccination programme. (Photo by JUSTIN TALLIS / AFP)

The European Medicines Agency has recommended approving Johnson & Johnson's single dose Covid vaccine after a successful trial.

Advertisement

"The European Medicines Agency has recommended granting a conditional marketing authorisation for COVID-19 Vaccine Janssen (made by Johnson & Johnson) to prevent COVID-19 in people from 18 years of age," read a statement from the EMA on Thursday.

Results from a trial of about 44,000 participants show the jab was 67 percent effective in preventing moderate-to-severe Covid globally.

https://twitter.com/EMA_News/status/1370002324605853701

The jab is the fourth to be endorsed for use in the EU after vaccines from Pfizer-BioNTech , AstraZeneca-Oxford University and Moderna, and is recommended for those over 18 years of age, the European Medicines Agency (EMA) said.

"With this latest positive opinion, authorities across the European Union will have another option to combat the pandemic and protect the lives and health of their citizens. This is the first vaccine that can be used as a single dose," said Emer Cooke, EMA’s Executive Director.

The side effects with COVID-19 Vaccine Janssen in the study were usually mild or moderate and cleared within a couple of days after vaccination, the EMA said.

Advertisement

The most common ones were pain at the injection site, headache, tiredness, muscle pain and nausea.

"The safety and effectiveness of the vaccine will continue to be monitored as it is used across the EU, through the EU pharmacovigilance system and additional studies by the company and European authorities," said the EMA.

The European Commission will now fast-track the decision-making process to grant a decision on the conditional marketing authorisation for COVID-19 Vaccine Janssen, allowing vaccination programmes to be rolled out across the EU.

More

Join the conversation in our comments section below. Share your own views and experience and if you have a question or suggestion for our journalists then email us at [email protected].
Please keep comments civil, constructive and on topic – and make sure to read our terms of use before getting involved.

Please log in to leave a comment.

Anonymous 2021/03/12 09:23
I cant imagine too many Germans wanting a vaccine that is only 67% effective ....

See Also